Structure Therapeutics (NASDAQ:GPCR) Trading 4.8% Higher – What’s Next?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s share price traded up 4.8% during mid-day trading on Friday . The stock traded as high as $48.60 and last traded at $48.2490. 283,921 shares were traded during trading, a decline of 70% from the average session volume of 933,298 shares. The stock had previously closed at $46.03.

Analysts Set New Price Targets

GPCR has been the subject of a number of analyst reports. Wall Street Zen lowered shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Wolfe Research assumed coverage on shares of Structure Therapeutics in a research report on Thursday, March 26th. They set a “peer perform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. HC Wainwright decreased their price objective on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, June 11th. Finally, Canaccord Genuity Group started coverage on Structure Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating and a $101.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Structure Therapeutics Price Performance

The stock has a market cap of $3.48 billion, a price-to-earnings ratio of -56.15 and a beta of -1.50. The firm’s 50-day moving average is $44.15 and its 200 day moving average is $56.58.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.04. On average, sell-side analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

A number of large investors have recently modified their holdings of GPCR. Geode Capital Management LLC grew its holdings in shares of Structure Therapeutics by 18.5% during the 2nd quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock worth $1,124,000 after purchasing an additional 8,444 shares during the period. Invesco Ltd. raised its holdings in Structure Therapeutics by 7.6% in the second quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock valued at $8,805,000 after buying an additional 30,162 shares during the period. Marshall Wace LLP lifted its position in Structure Therapeutics by 474.9% during the second quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock valued at $3,651,000 after buying an additional 145,434 shares in the last quarter. Jump Financial LLC lifted its position in Structure Therapeutics by 105.9% during the second quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock valued at $1,311,000 after buying an additional 32,524 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in Structure Therapeutics during the second quarter worth approximately $3,480,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.